My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Abbott Laboratories (NY:ABT)

135.19 -0.70 (-0.52%)
Streaming Delayed Price Updated: 1:28 PM EDT, Sep 24, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Abbott Laboratories

< Previous 1 2 3 4 5 6 7 8 9
...
48 49 Next >
1 Mooning Stock with Exciting Potential and 2 to Think Twice About
Each stock in this article is trading near its 52-week high. These elevated prices usually indicate some degree of investor confidence, business improvements, or favorable market conditions. 
Via StockStory
ABBOTT LABORATORIES (NYSE:ABT) - A Strong Technical Setup for Breakout Investors
ABBOTT LABORATORIES (NYSE:ABT) shows strong technicals and a high-quality setup, making it a potential breakout candidate for traders. 
Via Chartmill
3 Stocks With 3% to 9% Yields Just Raised Dividends Again
Via MarketBeat
Goldman Sachs Bullish On Dexcom And Insulet As Diabetes Tech Surges
Goldman Sachs forecasts strong growth for diabetes tech, backing Dexcom and Insulet while rating Tandem and Beta Bionics as Neutral. 
Via Benzinga
How Boston Scientific's Surprise Setback Bolstered Edwards, Medtronic, Abbott
The company said the regulatory path forward for one of its key systems is too murky to pursue. 
Via Investor's Business Daily
2 Dividend Stocks to Buy With $500 and Hold Forever
Via The Motley Fool
ABBOTT LABORATORIES (NYSE:ABT) – A Quality Stock Worth Considering
ABBOTT LABORATORIES (NYSE:ABT) meets key quality investing criteria with strong revenue growth, high ROIC, and excellent profit quality, making it a solid long-term candidate. 
Via Chartmill
3 Magnificent Stocks That Are Passive Income Machines
Via The Motley Fool
What's going on in today's session: S&P500 movers
Join us in exploring the top gainers and losers within the S&P500 index in the middle of the day on Thursday as we examine the latest happenings in today's session. 
Via Chartmill
$34 Billion Market in 2025 Advancing to $45 Billion in 2026 for Phase III Development of New Blood Thiner, Less Problematic Than Warfrain: Cadrenal Therapeutics, Inc. (Nasdaq: CVKD)
Via Get News
Topics Death Economy
Recent Filing Shows That Rep. Bruce Westerman Sold Over $137K Worth of Apple Stock
 
Via Benzinga
ABBOTT LABORATORIES (NYSE:ABT) - A Strong Technical Setup for Breakout Investors
ABBOTT LABORATORIES (NYSE:ABT) shows strong technicals and a high-quality breakout setup, supported by institutional interest and clear support/resistance levels. 
Via Chartmill
Reflecting On Medical Devices & Supplies - Diversified Stocks’ Q1 Earnings: Abbott Laboratories (NYSE:ABT)
As the Q1 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the medical devices & supplies - diversified industry, including Abbott Laboratories... 
Via StockStory
1 Mega-Cap Stock Worth Your Attention and 2 to Keep Off Your Radar
"Too big to fail" is how we would describe the megacap stocks in this article today. While they will likely stand the test of time, it’s not all sunshine and rainbows as their scale can limit their... 
Via StockStory
Jensen Huang, Magic Johnson, Patrick Dempsey, Linda Yaccarino And More Bigwigs Headline Milken Global Conference 2025: What You Need To Know
The Milken Institute's 28th annual Global Conference, featuring prominent figures like Jensen Huang, Magic Johnson, and Linda Yaccarino, is focusing on key global issues such as AI, healthcare, and... 
Via Benzinga
Topics Artificial Intelligence
Here Are All the Dividend Kings Beating the S&P 500 in 2025 -- and the 2 That Are the Best Stocks to Buy Now
Via The Motley Fool
Topics Government Stocks World Trade
2 Stocks, 2 Decades, $200. Is This the Long-Term Dividend Play for Your Portfolio?
Via The Motley Fool
If A Recession Hits, Will Medical Stocks Be A Safe Haven For Investors — Again?
Medical stocks are usually considered defensive. But have they been too hammered by regulatory changes to hold up this year? 
Via Investor's Business Daily
Topics Animal Testing Economy Government
Abbott Laboratories (NYSE:ABT) Shows Strong Technical Breakout Potential
Abbott Laboratories (NYSE:ABT) Shows Strong Technical Breakout Potential 
Via Chartmill
A Look Into Abbott Laboratories Inc's Price Over Earnings
 
Via Benzinga
3 Dividend Stocks to Buy and Hold for the Next Decade
Via The Motley Fool
If You Wanted To Buy AbbVie and Didn’t, There’s Still Time To Buy
AbbVie is well-positioned for industry-leading growth, as Skyrizi and Rinvoq sales outperform, driving system-wide growth alongside a diversified portfolio. 
Via MarketBeat
What To Expect From Penumbra’s (PEN) Q1 Earnings
Medical device company Penumbra (NYSE:PEN) will be reporting results tomorrow after the bell. Here’s what investors should know. 
Via StockStory
Topics Artificial Intelligence
Earnings To Watch: ResMed (RMD) Reports Q1 Results Tomorrow
Medical device company ResMed (NYSE:RMD) will be announcing earnings results tomorrow after market close. Here’s what to look for. 
Via StockStory
Topics Artificial Intelligence
What To Expect From Boston Scientific’s (BSX) Q1 Earnings
Medical device company Boston Scientific (NYSE:BSX) will be reporting results tomorrow before market open. Here’s what to look for. 
Via StockStory
Topics Economy
Earnings To Watch: Intuitive Surgical (ISRG) Reports Q1 Results Tomorrow
Medical technology company Intuitive Surgical (NASDAQ:ISRG) will be reporting results tomorrow after market close. Here’s what investors should know. 
Via StockStory
Topics Artificial Intelligence
10 Health Care Stocks Whale Activity In Today's Session
 
Via Benzinga
Dividend Stock Analysis: Abbott Laboratories
The company is focused on nutritionals, diagnostics, generic drugs, and medical devices. 
Via Talk Markets
Topics Stocks / Equities
These Analysts Boost Their Forecasts On Abbott Laboratories After Better-Than-Expected Earnings
 
Via Benzinga
Demystifying Abbott Laboratories: Insights From 11 Analyst Reviews
 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
48 49 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.